Articles by Louis Garguilo
-
3 Questions Of Risk And Communication In A Time Of Coronavirus
3/20/2020
Communication with your service providers may turn out most important in getting through immediate coronavirus-induced supply-chain challenges. Outsourcing may have got you into this situation; now it may be the only thing that can get you out.
-
Sign It, President Trump; Don't Go There, President Xi
3/17/2020
If drugs are discovered as purposefully held up by China to create a supply issue in the U.S., would you ever again employ a China-based CMO? Who would have thought Outsourced Pharma readers would be front and center in presidential politics? But you are.
-
Don't Spread The Wrong Message: COVID-19 And Respect For CMOs
3/13/2020
The first was to be a celebration for safely, reliably, and productively keeping drug development and manufacturing supply chains running. The second is a threat to shut those supply chains down. But here’s a second irony: This new coronavirus may have provided us an opportunity of sorts.
-
COVID-19 No-Fly Zone: A Year And Counting For Biopharma Supply Chains
3/4/2020
“Right now, the coronavirus situation is more about transportation than manufacture,” says one biopharma executive with a global supply chain. “If this continues for more than a year, then I think it'll be getting products manufactured that will really be in play.”
-
Will We Learn The Right Lessons From The Coronavirus Crisis?
2/18/2020
What happens – or continues not to happen – next with the coronavirus is critical to the future of global pharmaceutical development and manufacturing industry’s supply chains. But what lessons will we draw from the crisis?
-
Coronavirus: Pharma To The Rescue Too Simple
2/3/2020
We may think we’ve been through this before with other coronaviruses such as SARS and MERS … but this time it feels different, like a larger confluence of too many overlapping and unstable tectonic plates.
-
Biotechs Will Make Music In The “Twenty-Twenties”
11/27/2019
Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.
-
CDMO-To-Hospital: A Direct Ending For Generic Shortages?
8/1/2019
Part 2 of our look at the unique business model and ambitious plans of Civica Rx.
-
Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit
7/1/2019
The nonprofit CivicaRX continues to gain momentum, and the company’s president and CEO, Martin Van Trieste, believes it’s a business model that is “pro-competition,” and one that others throughout the biopharma industry can adapt as well.
-
I Outsource, Therefore I Exist
3/1/2019
Today, the success of your programs has never been more contingent upon selecting and working effectively with your service partners. This is what our annual CMO Leadership Awards are all about.